Skip to main content
Equibles
PVLA logo

PVLA · Palvella Therapeutics, Inc.

Track PVLA — free

Use PVLA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$149.97 -0.36 (-0.24%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$2.18B
Shares
14.41M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$149.97 Open$148.65 Day$148.35–153.28 52W close$51.30–157.77 Avg vol 30d198K Short int2.1M · 14.9% float · 12.8d Short vol68% Last earningsAug 4, 2026 DataApr 2024–Aug 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Apr 23, 2024; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +28%
      above
      Price vs 50-day avg +3%
      above
      RSI (14) 52
      neutral
      MACD trend Negative
      52-week position 93%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +8%
      trailing
      6-month return +10%
      trailing
      YTD return +43%
      this year
      Relative strength −4%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $145 › 200d $117 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      14.92% of float · ▲ +3.9% MoM · 12.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      199 holders — near 2-yr high, broad support
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +65%
      Y/Y
      EPS growth +53%
      Y/Y
      Free cash flow $-25.2M
      Quant / Vol
      risk profile
      Very High
      Volatility 84%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 5.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 4, 2026
      Anticipated full-year 2026 cash expenses · full-year 2026 Initiated $85M – $95M
      Prior guidance period ended · from the 8-K filed Nov 10, 2025
      Projected cash at year end · year end $55M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +28% Bullish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      52 Neutral
      MACD trend
      Negative Bearish
      52-week position
      93% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $145 › 200d $117 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      14.92% of float · ▲ +3.9% MoM · 12.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      199 holders — near 2-yr high, broad support
      Price context
      position in its 52-week range
      Range low $51 Now $150 · 93% Range high $158
      vs 200-day avg +28% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash, cash equivalents and short-term investments $250.6M as of June 30, 2026 —
      Shares outstanding 15,802,768 as of July 31, 2026 —
      Weighted average shares outstanding for calculation of EPS 14,356,219 Q2 2026 —
      Cash $262M 3/31/26 —
      Oversubscribed Financing $230M Feb. 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PVLA
      Palvella Therapeutics, Inc.
      this stock
      		$2.18B +43.3% +65.3% — 14.9%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $137.30B +19.5% +46.2% 31.6 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $81.27B +2.9% +20.8% 19.6 2.3%
      ARGX
      Argenx SE
      		 $63.63B +21.7% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.23B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      199
      % held
      101.1%
      Net QoQ
      +842.8K sh
      Top holder
      SUVRETTA CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      184
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.1M
      Days to cover
      12.8d
      Change
      +81.3K sh
      View
      Short Volume
      Short vol %
      68%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      148
      Value
      $22.2K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      40.8%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $42.8M
      Net income (FY)
      $-41.7M
      EPS diluted
      $-3.71
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      23
      View
      Proposed Sales
      Value
      $647.1K
      Shares
      4.3K
      Filed
      Aug 19, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Apr 23, 2024; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      PVLA +5.6% +7.9% +9.7% +7.9% +43.3%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY +5.1% +4.9% -3.7% +4.9% +30.5%
      Key facts CIK 1583648 CUSIP 697947109 13F (30d) 175 filings 172 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)